Jardiance and Prednisone Interaction: What Clinicians and Patients Should Know

The direct answer

Empagliflozin (Jardiance) and prednisone can be taken together; no drug interaction database or FDA label treats this combination as contraindicated. The interaction is pharmacodynamic rather than pharmacokinetic: prednisone increases hepatic glucose production and worsens insulin resistance, while empagliflozin lowers glucose independently of insulin by blocking renal glucose reabsorption. In most patients the steroid effect dominates, so blood glucose tends to rise during a prednisone course even in patients well controlled on empagliflozin. The clinically important add-on risk is euglycemic diabetic ketoacidosis, a documented but uncommon SGLT2 inhibitor complication in which ketones rise despite glucose readings that look reassuring; because glucocorticoids independently increase lipolysis and ketogenic substrate, clinicians should have a lower threshold to check ketones in this combination even when glucose looks acceptable.

Disambiguating the two drugs

Jardiance (empagliflozin) is an SGLT2 (sodium-glucose cotransporter-2) inhibitor. It is FDA-approved for type 2 diabetes, for reducing cardiovascular death risk in adults with heart failure across the ejection fraction spectrum, and for slowing progression of chronic kidney disease in appropriate patients. It works in the kidney's proximal tubule and does not depend on insulin secretion or sensitivity.

Prednisone is a synthetic glucocorticoid corticosteroid used for a wide range of inflammatory and autoimmune conditions. It is metabolized to its active form, prednisolone, and acts on glucocorticoid receptors throughout the body, including the liver, muscle, and adipose tissue.

Why they interact without interacting metabolically

Empagliflozin is cleared largely through glucuronidation, and prednisone is metabolized through corticosteroid-specific pathways. There is no established cytochrome P450 or transporter-based interaction between the two drugs described in either drug's FDA label. The clinically relevant "interaction" is physiological, not metabolic: the two drugs act on glucose through different, competing mechanisms, and the FDA labels for each drug separately note that other agents affecting glucose or insulin action can shift the net glycemic picture.

This is the core, load-bearing fact for the whole page: empagliflozin and prednisone do not share a metabolic pathway, so there is no dose-adjustment rule based on drug clearance; the only reason to change management is the opposing and additive effect each drug has on blood glucose and, less directly, on ketone production.

What is established

• Glucocorticoids, including prednisone, are a recognized and common cause of drug-induced hyperglycemia. This is stated in the FDA prescribing information for corticosteroids and is widely reflected in endocrinology and hospital medicine practice, though the exact percentage of patients affected varies by study population, dose, and duration, and specific incidence numbers should be verified against a current primary source before being cited precisely.
• SGLT2 inhibitors, including empagliflozin, carry an FDA drug safety communication warning about the risk of ketoacidosis that can occur with near-normal blood glucose (euglycemic DKA). This is an FDA-level regulatory finding, not a single-study estimate. This has been described in FDA safety communications regarding this drug class, though the specific communication is not linked here and should be verified directly with the FDA.
• Neither the Jardiance label nor the prednisone label lists the other as a contraindicated combination or specifies a required dose change when co-administered.
• Empagliflozin's glucose-lowering mechanism (renal glucose excretion) is independent of insulin, so it continues to function even when insulin resistance from steroids increases; it simply may not be sufficient on its own during a significant steroid course.

What is pharmacologically plausible but not established by a specific trial cited here

• That combining a glucocorticoid with an SGLT2 inhibitor meaningfully raises euglycemic DKA risk above the baseline SGLT2 inhibitor risk. The mechanistic logic (increased lipolysis and ketogenic substrate from steroids, on top of a drug class already associated with ketoacidosis) is reasonable, and case reports of this combination causing euDKA appear in the endocrinology literature, but this page cannot point to a verified, specific incidence figure for the combined risk. Anyone writing a clinical protocol around this should search current literature directly rather than rely on an unverified number.
• That a specific empagliflozin dose increase (for example, 10 mg to 25 mg) reliably offsets a specific magnitude of steroid-induced glucose rise. This is a reasonable clinical maneuver in practice but is not something this page can back with a verified trial number.
• That prophylactic antifungal therapy is warranted during concurrent steroid and SGLT2 inhibitor use. This is plausible for patients with a history of recurrent genital candidiasis but is a judgment call, not a guideline mandate documented here.

What is not established here and should not be asserted as fact

• Precise percentages for how many patients on prednisone develop hyperglycemia, and precise mg/dL figures for expected glucose rise, cannot be confirmed from verifiable sources in this draft. Earlier versions of this type of content sometimes present numbers (such as "32-64%" or "68 mg/dL after a single dose") that look authoritative but were not traceable to a specific, checkable study here. Treat any such number as needing direct verification before use in a chart note or patient handout.
• Named clinician quotations describing personal prescribing practice around this specific drug combination could not be verified against a checkable source and have been removed rather than reproduced.
• Specific trial-derived numbers for cardiorenal benefit, fracture risk, or genital infection rates that appeared in earlier drafts of this topic should be re-confirmed against the current FDA label and the primary trial publications before being restated with precision.

Evidence-status interaction assessment

A practical monitoring approach

For any patient on empagliflozin who starts prednisone, a reasonable, conservative approach is:

More frequent glucose checks. Check blood glucose more often than usual during the steroid course, with particular attention to afternoon and evening readings, since corticosteroid-driven glucose elevation typically shows up later in the day rather than in the fasting state.

Ketone awareness, not just glucose awareness. Because SGLT2 inhibitors can cause ketoacidosis with glucose readings that look acceptable, check blood or urine ketones if the patient develops nausea, vomiting, abdominal pain, or unusual fatigue, even if the glucose meter reading is not markedly high. This is the single most clinically important point on this page: euglycemic DKA is easy to miss precisely because the glucose number looks reassuring.

Reassess renal function before starting. SGLT2 inhibitors lose most of their glucose-lowering efficacy at low eGFR, though cardiorenal benefits in the approved indications persist at lower eGFR thresholds per the current FDA label. Confirm current renal function before assuming empagliflozin will meaningfully help control steroid-induced hyperglycemia.

Plan for insulin if the steroid course is significant. For higher-dose or longer prednisone courses, empagliflozin alone is unlikely to be sufficient, and insulin is the standard fallback in both inpatient and outpatient glucocorticoid-hyperglycemia management. The specific insulin regimen and dose is an individualized clinical decision and is not something this page can specify for a given patient.

Do not stop empagliflozin reflexively. Empagliflozin is often prescribed for heart failure or chronic kidney disease independent of diabetes status, and that benefit is a separate clinical question from glucose control. Whether to pause an SGLT2 inhibitor during a high-dose or prolonged steroid course, similar to guidance around acute illness or surgery, is a judgment call that should involve the prescribing clinician rather than a default rule.

Bone health and infection risk, briefly

Prednisone is a well-established cause of secondary osteoporosis, and any patient on a meaningful prednisone dose for an extended period should be evaluated for bone-protective therapy under standard rheumatology or endocrinology guidance. Empagliflozin's own effect on bone and fracture risk has been studied in its major cardiovascular and renal outcome trials; the general takeaway is that empagliflozin does not appear to add meaningfully to fracture risk, but this should not be read as compensating for steroid-related bone loss, which needs its own management.

Separately, SGLT2 inhibitors are associated with increased genital mycotic infection risk because of glycosuria, and corticosteroids can suppress local immune defenses. Whether the combination raises infection risk beyond either drug alone has not been specifically quantified in a source this page can point to. Practical counseling (hygiene, prompt reporting of symptoms) is reasonable regardless.

When to seek urgent care

A patient on this combination should seek urgent evaluation for:

• Nausea, vomiting, abdominal pain, or rapid or labored breathing, regardless of the glucose meter reading
• Blood glucose persistently above the level their prescriber has identified as a danger threshold
• Inability to keep fluids down
• Any symptom consistent with a urinary or genital infection that is worsening rather than improving

These are general safety thresholds; individualized targets should come from the prescribing clinician, not from this page.

Evidence boundary summary

Established: the two drugs do not interact metabolically, both drugs affect glucose through well-described independent mechanisms, prednisone generally raises glucose more than empagliflozin can offset, and SGLT2 inhibitors carry an FDA-recognized euglycemic DKA risk.

Plausible but unproven with a specific number: that glucocorticoids meaningfully add to euglycemic DKA risk on top of the SGLT2 inhibitor's baseline risk, and that particular dose-adjustment strategies produce a specific, predictable glucose offset.

Not established here: precise incidence percentages for steroid-induced hyperglycemia in this specific population, a quantified combined DKA risk figure, and any physician quotation specific to managing this exact drug pair.